UK Markets closed
  • NIKKEI 225

    27,346.88
    +19.77 (+0.07%)
     
  • HANG SENG

    22,072.18
    +229.85 (+1.05%)
     
  • CRUDE OIL

    77.16
    -1.71 (-2.17%)
     
  • GOLD FUTURES

    1,968.00
    +22.70 (+1.17%)
     
  • DOW

    34,096.11
    +10.07 (+0.03%)
     
  • BTC-GBP

    19,045.42
    +276.95 (+1.48%)
     
  • CMC Crypto 200

    535.78
    +293.10 (+120.78%)
     
  • Nasdaq

    11,822.13
    +237.58 (+2.05%)
     
  • ^FTAS

    4,252.85
    -2.87 (-0.07%)
     

Target Healthcare REIT Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Target Healthcare REIT (LON:THRL) Full Year 2022 Results

Key Financial Results

  • Revenue: UK£63.9m (up 28% from FY 2021).

  • Net income: UK£49.1m (up 12% from FY 2021).

  • Profit margin: 77% (down from 88% in FY 2021). The decrease in margin was driven by higher expenses.

  • EPS: UK£0.082.

THRL Net Asset Value

  • Net asset value (NAV) per share: UK£1.13 (up 2.0% from FY 2021).

    • The current share price is 23% lower than NAV per share.

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Target Healthcare REIT Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the REITs industry in the United Kingdom.

Performance of the British REITs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Target Healthcare REIT that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here